JP7518765B2 - Ｄ－セリンの重水素化類似体およびその使用 - Google Patents

Ｄ－セリンの重水素化類似体およびその使用 Download PDF

Info

Publication number
JP7518765B2
JP7518765B2 JP2020528027A JP2020528027A JP7518765B2 JP 7518765 B2 JP7518765 B2 JP 7518765B2 JP 2020528027 A JP2020528027 A JP 2020528027A JP 2020528027 A JP2020528027 A JP 2020528027A JP 7518765 B2 JP7518765 B2 JP 7518765B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
deuterium
formula
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020528027A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021504326A (ja
JP2021504326A5 (https=
Inventor
ドラー，ダリオ
エル． ブランメル，クリストファー
エフ． リウ，ジュリー
ディー． タン，ロジャー
Original Assignee
コンサート ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンサート ファーマシューティカルズ インコーポレイテッド filed Critical コンサート ファーマシューティカルズ インコーポレイテッド
Publication of JP2021504326A publication Critical patent/JP2021504326A/ja
Publication of JP2021504326A5 publication Critical patent/JP2021504326A5/ja
Priority to JP2023091296A priority Critical patent/JP7733058B2/ja
Application granted granted Critical
Publication of JP7518765B2 publication Critical patent/JP7518765B2/ja
Priority to JP2025106389A priority patent/JP2025138735A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020528027A 2017-11-22 2018-11-21 Ｄ－セリンの重水素化類似体およびその使用 Active JP7518765B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023091296A JP7733058B2 (ja) 2017-11-22 2023-06-02 Ｄ－セリンの重水素化類似体およびその使用
JP2025106389A JP2025138735A (ja) 2017-11-22 2025-06-24 Ｄ－セリンの重水素化類似体およびその使用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762590109P 2017-11-22 2017-11-22
US62/590,109 2017-11-22
US201862636081P 2018-02-27 2018-02-27
US62/636,081 2018-02-27
US201862636427P 2018-02-28 2018-02-28
US62/636,427 2018-02-28
US201862755157P 2018-11-02 2018-11-02
US62/755,157 2018-11-02
PCT/US2018/062263 WO2019104179A1 (en) 2017-11-22 2018-11-21 Deuterated analogs of d-serine and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023091296A Division JP7733058B2 (ja) 2017-11-22 2023-06-02 Ｄ－セリンの重水素化類似体およびその使用

Publications (3)

Publication Number Publication Date
JP2021504326A JP2021504326A (ja) 2021-02-15
JP2021504326A5 JP2021504326A5 (https=) 2021-12-23
JP7518765B2 true JP7518765B2 (ja) 2024-07-18

Family

ID=64755715

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020528027A Active JP7518765B2 (ja) 2017-11-22 2018-11-21 Ｄ－セリンの重水素化類似体およびその使用
JP2023091296A Active JP7733058B2 (ja) 2017-11-22 2023-06-02 Ｄ－セリンの重水素化類似体およびその使用
JP2025106389A Pending JP2025138735A (ja) 2017-11-22 2025-06-24 Ｄ－セリンの重水素化類似体およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023091296A Active JP7733058B2 (ja) 2017-11-22 2023-06-02 Ｄ－セリンの重水素化類似体およびその使用
JP2025106389A Pending JP2025138735A (ja) 2017-11-22 2025-06-24 Ｄ－セリンの重水素化類似体およびその使用

Country Status (13)

Country Link
US (4) US20200368193A1 (https=)
EP (2) EP3713557B1 (https=)
JP (3) JP7518765B2 (https=)
KR (1) KR102916897B1 (https=)
CN (1) CN111491629A (https=)
AU (2) AU2018371784B2 (https=)
BR (1) BR112020010156A2 (https=)
CA (1) CA3082834A1 (https=)
IL (2) IL274585B2 (https=)
MX (1) MX2020005336A (https=)
PL (1) PL3713557T3 (https=)
TW (1) TWI886093B (https=)
WO (1) WO2019104179A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023123476A (ja) * 2017-11-22 2023-09-05 コンサート ファーマシューティカルズ インコーポレイテッド Ｄ－セリンの重水素化類似体およびその使用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2738873C2 (ru) * 2018-12-29 2020-12-17 Общество С Ограниченной Ответственностью "Сольвекс" (Ооо "Сольвекс") Препарат для магнитно-резонансной томографии, содержащий дейтерированный саркозин, и способ диагностики с использованием этого препарата
WO2020206367A1 (en) * 2019-04-03 2020-10-08 Concert Pharmaceuticals, Inc. Processes for the preparation of deuterated d-serine
WO2020243638A1 (en) * 2019-05-30 2020-12-03 Concert Pharmaceuticals, Inc. Methods of treatment with deuterated analogs of d-serine
EP4076461B1 (en) * 2019-12-19 2026-01-28 Intra-Cellular Therapies, Inc. Lumateperone for use in schizophrenia treatment
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002511409A (ja) 1998-04-14 2002-04-16 ザ ジュネラル ホスピタル コーポレーション 神経精神疾患の治療法
US20140187597A1 (en) 2003-02-06 2014-07-03 Sarah Herzog Memorial Hospital Ezrath Nashim Association Pharmaceutical compositions for the treatment of movement disorders
US20170326137A1 (en) 2013-05-28 2017-11-16 Sarah Herzog Memorial Hospital-Ezrath Nashim Autoimmune-Induced Glutamatergic Receptor Dysfunction Methods and Treatments

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582931A (en) 1984-12-24 1986-04-15 Merck & Co., Inc. Preparation of 2-Deutero-D-serine
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6361957B1 (en) 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
PT871440E (pt) 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
US5845286A (en) 1996-12-24 1998-12-01 Colizza; Vincent Date value reduction system
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
US6258605B1 (en) 1999-03-26 2001-07-10 Neo Gen Screening, Inc. Clinical method for the genetic screening of newborns using tandem mass spectrometry
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
PT1104760E (pt) 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
HU229938B1 (en) 2001-05-03 2015-01-28 Hoffmann La Roche Pharmaceutical dosage form of amorphous nelfinavir mesylate
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
US20060094744A1 (en) 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
CA2602626A1 (en) 2005-04-11 2006-10-19 Yale University Method of treating schizophrenia prodrome
CN101309917B (zh) 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
WO2008030382A1 (en) 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
IL188681A0 (en) 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
WO2012019106A2 (en) 2010-08-06 2012-02-09 Board Of Regents Of The University Of Nebraska Positive and negative modulators of nmda receptors
US9040581B1 (en) 2013-02-21 2015-05-26 The Florida State University Research Foundation, Inc. Methods of treatment using D-serine
WO2014205074A2 (en) 2013-06-18 2014-12-24 The Trustees Of Columbia University In The City Of New York Devices, compositions and methods for imaging with raman scattering
WO2015160470A2 (en) * 2014-03-20 2015-10-22 The Trustees Of Princeton University Nadph production by the 10-formyl-thf pathway, and its use in the diagnosis and treatment of disease
GB201521903D0 (en) 2015-12-11 2016-01-27 Electrophoretics Ltd Isorbaric mass labels
EP3465202B1 (en) 2016-06-02 2023-07-05 Metabolon, Inc. Mass spectrometry method for detection and quantitation of metabolites
CN111491629A (zh) * 2017-11-22 2020-08-04 康塞特医药品公司 D-丝氨酸的氘化类似物及其用途
WO2020243650A1 (en) 2019-05-29 2020-12-03 Concert Pharmaceuticals, Inc. Deuterated analogs of d-serine and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002511409A (ja) 1998-04-14 2002-04-16 ザ ジュネラル ホスピタル コーポレーション 神経精神疾患の治療法
US20140187597A1 (en) 2003-02-06 2014-07-03 Sarah Herzog Memorial Hospital Ezrath Nashim Association Pharmaceutical compositions for the treatment of movement disorders
US20170326137A1 (en) 2013-05-28 2017-11-16 Sarah Herzog Memorial Hospital-Ezrath Nashim Autoimmune-Induced Glutamatergic Receptor Dysfunction Methods and Treatments

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Advances in Drug Research，1985年，Vol.14，p.1-40
Analytical Biochemistry，2013年，Vol.432，No.2，p.124-130
MEDCHEM NEWS，2014年，No.2，p.8-22
Schizophrenia Research，2010年，Vol.121，No.1-3，p.125-130
The FEBS Journal，2012年，Vol.279，No.4，p.612-624

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023123476A (ja) * 2017-11-22 2023-09-05 コンサート ファーマシューティカルズ インコーポレイテッド Ｄ－セリンの重水素化類似体およびその使用
JP7733058B2 (ja) 2017-11-22 2025-09-02 コンサート ファーマシューティカルズ インコーポレイテッド Ｄ－セリンの重水素化類似体およびその使用

Also Published As

Publication number Publication date
AU2025200345A1 (en) 2025-02-13
US10668036B2 (en) 2020-06-02
JP2023123476A (ja) 2023-09-05
CA3082834A1 (en) 2019-05-31
US20200390732A1 (en) 2020-12-17
US20200368193A1 (en) 2020-11-26
JP7733058B2 (ja) 2025-09-02
KR20200103662A (ko) 2020-09-02
US20190328692A1 (en) 2019-10-31
IL274585B1 (en) 2025-09-01
KR102916897B1 (ko) 2026-01-26
JP2021504326A (ja) 2021-02-15
MX2020005336A (es) 2020-08-13
US12029712B2 (en) 2024-07-09
IL274585B2 (en) 2026-01-01
US20250000830A1 (en) 2025-01-02
EP4560024A2 (en) 2025-05-28
TW201924668A (zh) 2019-07-01
WO2019104179A1 (en) 2019-05-31
IL274585A (en) 2020-06-30
CN111491629A (zh) 2020-08-04
BR112020010156A2 (pt) 2020-11-10
PL3713557T3 (pl) 2025-09-22
EP3713557B1 (en) 2025-03-12
IL322463A (en) 2025-09-01
EP4560024A3 (en) 2025-08-20
EP3713557A1 (en) 2020-09-30
AU2018371784A1 (en) 2020-05-28
AU2018371784B2 (en) 2024-10-17
WO2019104179A4 (en) 2019-08-01
JP2025138735A (ja) 2025-09-25
TWI886093B (zh) 2025-06-11

Similar Documents

Publication Publication Date Title
JP7518765B2 (ja) Ｄ－セリンの重水素化類似体およびその使用
CN110123820A (zh) 精氨酸酶抑制剂及其使用方法
CA2994404A1 (en) Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof
JP7475055B2 (ja) （ｓ）－３－アミノ－４－（ジフルオロメチレニル）シクロペンタ－１－エン－１－カルボン酸の合成法
JP2021501159A (ja) Ｃ５ａＲ阻害剤による尿中ｓＣＤ１６３の減少
WO2023170547A1 (en) Pure forms of crystalline aticaprant
CA3091924A1 (en) Amide prodrugs of small molecule nuclear receptor modulators
US20220313640A1 (en) Deuterated analogs of d-serine and uses thereof
CA2864797C (en) Methods of treating amyotrophic lateral sclerosis
EA050051B1 (ru) Дейтерированные аналоги d-серина и их применение
JP2025515371A (ja) Ｎｌｒｐ３インフラマソーム阻害剤としての化合物および医薬品としてのその使用
US20220218641A1 (en) Methods of treatment with deuterated analogs of d-serine
ES2694202T3 (es) Idebenona deuterada
TWI913215B (zh) 減少尿液sCD163之C5aR抑制劑
EP4304655A1 (en) Fatty acid-bifunctional degrader conjugates and their methods of use
AU2023378681A1 (en) Crystalline carbazole derivative and methods of making thereof
CN121930131A (zh) 化合物及其在治疗nmdar相关疾病中的用途
JP2025535312A (ja) フェネチルアミンおよびカチノンならびにそれらの立体異性体およびそれらの前駆体の調製
WO2020046941A1 (en) Crystalline forms of substituted dihydroindene-4-carboxamide compounds and methods of preparing and using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240603

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240705

R150 Certificate of patent or registration of utility model

Ref document number: 7518765

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150